Red and Blue Light Therapy for Periodontitis: What the Research Shows About Treating Advanced Gum Disease

What Is Periodontitis and How Does It Differ from Gingivitis?

Gingivitis is inflammation confined to the gum tissue. The bone and ligament anchoring the teeth remain intact, and the condition is fully reversible with proper care. Periodontitis is what happens when that inflammation persists and advances: the immune response, initially triggered by bacterial infection, begins destroying the periodontal ligament and alveolar bone that hold teeth in their sockets. Pockets form between the teeth and gums, deepening as tissue and bone are lost. At its most advanced, teeth loosen and fall out.

The bacterium most responsible for driving this progression is Porphyromonas gingivalis, a keystone pathogen that thrives in the oxygen-poor environment below the gumline. What makes P. gingivalis especially dangerous is its ability to actively suppress the host immune response, therefore breaking down immune signals, blocking immune cell recruitment, and creating conditions that favor the growth of other pathogenic species. The result is a biofilm community that is highly resistant to the body's own defenses and difficult to eliminate by mechanical cleaning alone (Gasmi Benahmed et al., 2022).

This matters beyond the mouth. A joint consensus report by the European Federation of Periodontology and WONCA Europe, published in the Journal of Clinical Periodontology, concluded that periodontitis is independently associated with cardiovascular disease, type 2 diabetes, chronic obstructive pulmonary disease, obstructive sleep apnea, and adverse COVID-19 outcomes. The report further confirmed that treatment of periodontitis has been associated with improvements in systemic health outcomes (Herrera et al., 2023). A large-scale meta-analysis of 15 cohort studies involving 427,620 participants quantified the bidirectional relationship: periodontitis increases diabetes risk by 26%, and diabetes increases periodontitis risk by 24% (Stöhr et al., 2021). A 2025 review in the Journal of Dental Research (one of the field's highest-impact journals) confirmed that periodontal therapy reduces HbA1c by approximately 0.43%, and identified oral dysbiosis, systemic inflammation, and impaired nitric oxide pathways as the mechanistic links between the two conditions (Graves et al., 2025).

Standard treatment for periodontitis is scaling and root planing (SRP), a deep cleaning that removes the bacterial biofilm and calculus from below the gumline. SRP is effective at halting disease progression. What it cannot do is regenerate bone and ligament that have already been destroyed. Surgical options exist such as guided tissue regeneration, bone grafting, and biologic agents, but surgery requires specialist referral, carries higher cost, involves recovery time, and is not appropriate for every patient or defect type. For a large number of patients, there is a clinical gap between "SRP helped, but the damage is still there" and "surgery." Light therapy addresses that gap through biological mechanisms that reduce bacterial load, control inflammation, and stimulate the repair pathways that standard mechanical treatment cannot activate.

How Red Light Therapy Addresses Periodontitis

Red light therapy, clinically known as photobiomodulation (PBM), operates at wavelengths between approximately 620 and 900nm. Its effects in periodontitis target four interconnected problems: chronic inflammation, impaired cellular energy, reduced tissue repair capacity, and bone loss.

Reducing the Inflammation That Destroys Tissue and Bone

Periodontitis is not simply an infection. It is an inflammatory disease in which the body's own immune response (when chronic and disproportionate) does most of the structural damage. Pro-inflammatory cytokines drive the destruction of periodontal ligament and alveolar bone. Reducing that inflammatory cascade without suppressing the immune system is the therapeutic challenge.

A 2022 cell culture study by Yamauchi and colleagues demonstrated that red LED light at 650nm significantly increased intracellular ATP (energy) production in human periodontal ligament stem cells and simultaneously reduced two key pro-inflammatory cytokines (IL-6 and IL-8) that had been triggered by inflammatory challenge. The critical finding was causal: when ATP production was chemically blocked, the anti-inflammatory effect disappeared. The inflammation reduction flows directly from the energy boost. They are not independent effects (Yamauchi et al., 2022).

This mechanism is directly relevant to periodontitis because mitochondrial dysfunction plays a critical role in the development and progression of oral inflammatory diseases, as confirmed by a 2023 review in the International Journal of Molecular Sciences. That review documented that gingival cells from chronic periodontitis patients show four- to five-fold reductions in mitochondrial membrane potential and oxygen consumption compared to healthy subjects, with an 18% increase in reactive oxygen species production (Dong et al., 2023). Restoring mitochondrial function through PBM addresses an underlying contributor to the disease, not just a symptom.

The oxidative stress dimension is also significant. Chen et al. (2021), in Photonics, exposed human gum cells to a bacterial toxin to mimic inflamed gingival conditions, then applied 630nm red light. The light lowered reactive oxygen species inside the cells, which in turn reduced an inflammation-driving enzyme (COX-2), which lowered the inflammatory signals themselves. This chain of cause and effect, i.e. reduced oxidative stress leading to reduced inflammation, demonstrates that PBM's anti-inflammatory action runs through multiple connected pathways (Chen et al., 2021).

A 2024 study by Tanum and colleagues, published in the Journal of Dental Research, provided the most clinically relevant laboratory model to date. They exposed human gum surface cells to live P. gingivalis, F. nucleatum, and Candida albicans, then applied photobiomodulation. The treated cells produced significantly more antimicrobial peptides, showed enhanced survival and proliferation, reduced pro-inflammatory signaling (downregulating NF-κB via Nox2/4, MyD88, and TRAF6), improved clearance of reactive oxygen species, and maintained the structural integrity of the epithelial barrier. The treated gum cells also protected underlying fibroblasts from microbial damage in a three-dimensional co-culture system (Tanum et al., 2024). For periodontitis, where the gum barrier is compromised and bacteria have direct access to deeper structures, this dual strengthening (better defense with less inflammatory collateral damage) addresses the core pathology.

A 2023 study by Misra and colleagues confirmed the inflammatory mediator changes in a clinical setting. In a trial involving 40 patients and 240 periodontal sites, photobiomodulation added to open flap debridement produced significantly better wound healing scores at weeks 1 and 2, and significantly reduced TNF-α and MMP-8 (a matrix metalloproteinase that degrades periodontal tissue) in gingival crevicular fluid, while significantly increasing OPG (osteoprotegerin, a marker of bone protection) at 6 months (Misra et al., 2023).

Activating Bone Regeneration Pathways

The distinction between gingivitis and periodontitis is bone loss. The most important question for periodontitis patients is whether light therapy can support bone regeneration, not just soft tissue healing.

A 2025 randomized controlled trial by Prakash and colleagues provides the strongest molecular evidence published to date. The study involved 64 periodontal intra-bony defect sites, randomized to simplified papilla preservation flap (SPPF) alone or SPPF with adjunctive low-level laser therapy. Patients were followed for one year. The laser group showed statistically significant improvements in probing depth, clinical attachment level, and radiographic defect depth at both 6 months and 12 months (p<0.05). At the molecular level, three bone formation markers (RUNX2, BMP-2, and COL-1) were significantly elevated in the laser group. RUNX2 is the master transcription factor for osteoblast differentiation. BMP-2 is a key signaling molecule that initiates bone formation. COL-1 is the primary structural protein of bone matrix. Their simultaneous upregulation indicates that PBM is activating the biological machinery of bone regeneration, not just reducing inflammation (Prakash et al., 2025).

Supporting this, a 2025 meta-analysis by Wei and colleagues pooled data from eight studies on low-level laser therapy in periodontal intra-bony defects. The meta-analysis found that probing depth reduction at 3 months was significantly greater in the laser group compared to controls (p=0.02), and clinical attachment level increase at 3 months was significantly greater in the laser group (p<0.001) (Wei et al., 2025). These are the defects that define periodontitis, not shallow gingival inflammation, but the craters in bone where the disease has already done its damage.

The stem cells most relevant to this regeneration are periodontal ligament stem cells (PDLSCs), which maintain and rebuild the entire tooth-support structure. Red LED light has been shown to promote both the proliferation and osteogenic differentiation of these cells (Wu et al., 2021). Kim et al. (2012), in the Journal of Dental Research, demonstrated that red LED light got PDLSCs to multiply and differentiate into bone-building cells. El-Dahab et al. (2024), in BMC Oral Health, found that infrared PBM switched on genes for stem-cell renewal and bone building in human PDLSCs, steering them toward rebuilding tooth-support tissue. Near-infrared light also strengthened connective tissue fibers and improved osteoblast activity in a beagle model (Kim et al., 2024). In human tissue, near-infrared laser light (940nm) accelerated bone formation in post-extraction tooth sockets, as shown by histological analysis (Nica et al., 2019), though extraction sockets and chronic periodontal defects are different clinical environments.

A 2025 systematic review of radiographic evidence (Sadeghian et al., 2025) found that 4 of 13 reviewed RCTs showed substantial enhancement in bone density and regeneration with PBM. The most current scoping review on laser-assisted periodontal regeneration (Bosisio et al., 2025) confirmed that RCTs reported improvements in probing depth reduction, clinical attachment gain, and radiographic bone fill when lasers were used as adjuncts to regenerative techniques, while noting that heterogeneity in laser parameters limits direct comparisons between studies.

Stimulating Gum Tissue Repair and Blood Flow

The soft tissue damage in periodontitis is also substantial. Gum recession exposes root surfaces, pockets deepen, and the tissue's capacity to regenerate declines, especially in older adults, where aging independently impairs each phase of wound repair (Decker et al., 2026).

Multiple independent studies confirm that red and near-infrared light increases the proliferation and migration of human gingival fibroblasts, the cells responsible for maintaining and rebuilding gum tissue. Karimi et al. (2024) found that three wavelengths of red and near-infrared light all increased fibroblast proliferation, with stronger adhesion and signs of active tissue formation. Singh et al. (2023) found that 660nm light improved fibroblast viability in cells from both older and younger individuals, partially compensating for age-related cellular decline. Mizrahi et al. (2026) found that 940nm near-infrared light at its highest tested dose lifted gingival fibroblast activity by roughly 19% above controls and selectively boosted cell migration.

For periodontitis patients, especially older adults whose cellular repair capacity is already declining, these mechanisms support the tissue recovery that resolves pocket depth and maintains the gum architecture around teeth.

Photobiomodulation also promotes angiogenesis, the formation of new blood vessels, in wound healing contexts, as confirmed by a systematic review by Zhang et al. (2022). Improved blood flow supports every other mechanism: delivering oxygen for ATP production, clearing inflammatory waste, and transporting immune cells.

The Clinical Evidence: Meta-Analyses and RCTs

The clinical evidence for red light therapy in periodontitis has matured significantly in the past two years. The strongest findings come from meta-analyses pooling data across multiple randomized controlled trials.

Gong 2025: the most comprehensive meta-analysis to date for patients with both periodontitis and type 2 diabetes, pooled data from six RCTs involving 319 patients. Adding PBM to scaling and root planing produced significant improvements in probing depth (−0.87mm; 95% CI: −1.00, −0.74; p<0.00001), clinical attachment level (−0.47mm; 95% CI: −0.65, −0.29; p<0.00001), fasting plasma glucose (−0.79 mmol/L; p=0.01), and systemic inflammation markers: hs-CRP (−0.99 mg/L; p<0.00001) and TNF-α (−2.78 pg/mL; p<0.00001). HbA1c showed borderline significant reduction (−0.81%, p=0.05). This meta-analysis is notable because it shows PBM improving periodontal, glycemic, and systemic inflammatory outcomes simultaneously in the highest-risk patient population (Gong, 2025). The authors noted high inter-study heterogeneity (most I² > 90%) and maximum 6-month follow-up as limitations.

da Silva et al. 2024: a broader systematic review of 22 clinical trials (with meta-analysis of 13), found that photobiomodulation with basic periodontal therapy reduced probing depth at 4-, 12-, and 24-week follow-up points and improved clinical attachment level at 6-, 12-, and 24-week follow-up points. Risk of bias was assessed as low in 16 of the 22 included studies (da Silva et al., 2024).

Laxmi et al. 2025: a meta-analysis of six RCTs found statistically significant improvements in probing depth (effect size: −0.94; 95% CI: −1.36, −0.52) and clinical attachment level (effect size: −0.44; 95% CI: −0.81, −0.06) at 6 months when PBM was added to standard scaling and root planing (Laxmi et al., 2025).

Corbella et al. 2023: published in Clinical Oral Investigations reviewed 11 RCTs involving 504 subjects with periodontitis and type 2 diabetes. Laser therapy as an adjunct to nonsurgical periodontal treatment showed significant probing depth and clinical attachment level improvement at 3 months, along with better HbA1c outcomes at 3 months (moderate certainty). This was published in a high-impact dental journal (Corbella et al., 2023).

Wevers et al. 2025: a systematic review and meta-analysis focused specifically on PBM outcomes in type 2 diabetes patients found modest but statistically significant improvements in clinical attachment level (−0.21mm) and probing depth (−0.25mm) in this high-risk population, while narrative synthesis of primary metabolic outcomes showed inconsistent effects (Wevers et al., 2025).

Individual RCTs add resolution to the meta-analytic picture. A 2025 RCT by Kaya Dadas and colleagues enrolled 68 patients in a three-group comparison (SRP vs. LANAP vs. LLLT). In moderate pockets (4–6mm) and deep pockets (≥7mm), laser-treated groups showed significant probing depth and clinical attachment reduction compared to controls, with LANAP showing significant bone filling on radiographic assessment at 3 months (Kaya Dadas et al., 2025). A 2018 clinical study by Petrović and colleagues randomized 60 patients with chronic periodontitis and found that the laser group (980nm) showed better clinical outcomes and significantly decreased prevalence of T. forsythia, T. denticola, P. gingivalis, A. actinomycetemcomitans, and P. intermedia (Petrović et al., 2018).

A 2022 randomized clinical trial involving 10 patients and 70 sites with stage III periodontitis found that LLLT added to open flap debridement produced significant improvements in gingival index, probing depth, relative attachment level, postoperative pain (at 24 hours and 3 days), and dentin hypersensitivity (at 1 week and 1 month) compared to open flap debridement alone (Shakoush et al., 2022).

How Blue Light Therapy Addresses Periodontitis

Blue light therapy operates at wavelengths between approximately 400nm and 470nm. Its primary mechanism in the mouth is antibacterial: blue light kills the specific bacteria that drive periodontitis by activating pigments those bacteria produce naturally. Everything described in this section works with light alone. No dye, no drug, no photosensitizing chemical. This is distinct from photodynamic therapy (PDT), which requires an externally applied agent.

Killing Periodontitis Pathogens Through Their Own Pigments

P. gingivalis produces endogenous porphyrins, which are light-sensitive pigments integral to the bacterium's iron-acquisition metabolism. When blue light reaches these pigments, it triggers a photochemical reaction that generates reactive oxygen species inside the bacterial cell, destroying it from within.

Yoshida et al. (2017), in Scientific Reports, confirmed that blue light kills P. gingivalis through this endogenous protoporphyrin IX mechanism, with singlet oxygen generation increasing in a dose-dependent manner. The bactericidal effect comes from oxidative DNA damage within the bacterial cells. No external photosensitizer was involved. Soukos et al. (2005), in Antimicrobial Agents and Chemotherapy, demonstrated that broadband visible light (380–520nm) rapidly and selectively kills oral black-pigmented bacteria in both pure cultures and dental plaque samples from patients with chronic periodontitis. The species killed included P. gingivalis, P. intermedia, P. nigrescens, and P. melaninogenica, with growth of these species reduced two- to three-fold after a single light exposure, while the remaining 36 species in the plaque showed substantially less suppression, confirming selective targeting of the pathogenic species.

This selectivity is critical for periodontitis management. Unlike broad-spectrum antibiotics or antiseptic rinses, blue light preferentially targets the species most responsible for disease progression while leaving beneficial species relatively unaffected.

Effective Under Anaerobic Conditions Where Periodontitis Lives

Periodontal pockets are anaerobic environments. The question of whether blue light works without oxygen is therefore not academic. It is the question. Hope et al. (2013) confirmed that blue light at 405nm kills P. gingivalis under strict anaerobic conditions, with kill rates reaching 94.1% at tested doses using a hand-held light source. A subsequent study by the same group confirmed similar anaerobic killing of Prevotella intermedia and P. nigrescens (Hope et al., 2016). The mechanism works in the conditions where the target bacteria actually live.

Disrupting Bacterial Replication and Communication

Beyond destroying existing cells, blue light impairs P. gingivalis's ability to reproduce. Chui et al. (2012) found that blue LED exposure suppressed genes responsible for chromosomal DNA replication and cell division, without any external chemical. Yuan et al. (2023) showed that blue light upregulated genes promoting heme uptake (RgpA, RgpB) and iron export (Ftn, FetB), while downregulating genes for hydroxyl radical scavenging, meaning the bacterium's own stress response works against it, accumulating more of the pigment that makes it vulnerable while losing the tools to neutralize the resulting damage.

Shany-Kdoshim et al. (2019) showed that blue light disrupts multi-species biofilm communities through both direct cell damage and a secondary bystander effect, where toxic molecules generated in one damaged cell propagate to neighboring cells within the biofilm structure, reducing biofilm thickness by approximately half.

No Resistance Development

No resistance to antimicrobial blue light has been observed in any published study. Comprehensive reviews by Wang et al. (2017) and Haridas et al. (2022) confirmed this. The mechanism is fundamentally different from antibiotics: rather than targeting a single molecular pathway, blue light exploits the bacteria's own essential pigments and damages multiple structures simultaneously. A bacterium that eliminated its porphyrin pigments would lose its iron-acquisition system, crippling its survival.

For periodontitis management, where repeated application over months and years is the goal, this absence of resistance is a meaningful advantage over antibiotics, where repeated use drives resistance, and over chlorhexidine, which disrupts the entire oral microbiome with extended use.

Blue Light's Contribution to Hard-Tissue Repair

Blue light's role in periodontitis extends beyond killing bacteria. Recent research has identified a separate pathway through which blue light directly promotes hard-tissue regeneration, an important finding for a disease defined by bone loss.

Chen et al. (2022), in the Journal of Photochemistry and Photobiology B, found that blue LEDs drove human dental pulp stem cells toward osteogenic (bone-building) differentiation through a calcium-channel receptor called TRPV1. Blue light raised the receptor's activity and the calcium signaling inside the cell, and blocking TRPV1 wiped out the effect. Kim et al. (2023) confirmed this in living tissue, showing blue light followed by near-infrared switched on bone-building pathways, with the near-infrared step afterward reducing potential toxicity. This means the mouth has at least two separate light-sensing pathways for tissue repair. Cytochrome c oxidase for red and near-infrared light, and TRPV1 for blue, which provides a mechanistic rationale for combining wavelengths (Chen et al., 2022; Kim et al., 2023).

Blue light also contributes to soft-tissue healing. Magni et al. (2022), in Life, showed blue LED light promotes wound healing through processes coordinated by immune cells called mast cells, with increased collagen deposition. Rossi et al. (2021), in Biomedicines, confirmed that blue light increases gum cell proliferation and migration at appropriate doses. These wound-healing contributions are in addition to, and independent of, the antibacterial mechanism (Magni et al., 2022; Rossi et al., 2021).

Blue Light Safety for Gum Tissue

Gait-Carr et al. (2026) tested 457nm blue and 415nm violet light on two types of human gum cells across a wide dose range. Blue light at 457nm caused only minor, non-significant drops in one cell type and boosted activity in the other. The distinction between blue and shorter violet wavelengths matters: the blue wavelengths used in oral-care devices appear safe at therapeutic doses, while shorter wavelengths carry more risk at higher doses. Yuan et al. (2023) confirmed the selective toxicity directly: 405nm blue light killed P. gingivalis while sparing human gingival fibroblasts.

The Clinical Evidence for Blue Light in Periodontitis

The most direct clinical evidence comes from Mujić Jahić et al. (2024), in a randomized controlled trial enrolling 31 patients with chronic periodontitis and treating a total of 862 periodontal pockets. Patients were randomly assigned to scaling and root planing alone or scaling plus 445nm blue laser therapy. All clinical parameters improved from baseline to three months in both groups. The blue light group showed greater improvements across every measured parameter: plaque index, gingival index, bleeding on probing, and probing depth. Probing depth in the blue-light group dropped from 4.61mm to 2.71mm (a 1.90mm reduction), compared to 4.40mm to 3.48mm (a 0.92mm reduction) in the standard treatment group. Microbiological analysis confirmed significantly greater reductions in P. gingivalis and T. forsythia in the blue-light group.

Supporting the clinical findings, the first confirmation of blue light's antibacterial effect in living patients came from Soukos et al. (2015), in Lasers in Medical Science. Blue light at 455nm was applied to the outer surfaces of premolar and molar teeth on one side of the mouth, twice daily for two minutes over four days, in eleven people. On the treated side, P. gingivalis fell by about 25% and P. intermedia by about 56%, with no change on the untreated side, and gum redness decreased on the treated side while increasing on the untreated side (Soukos et al., 2015).

This study used a professional-grade laser. The wavelength (445nm) and the biological mechanism (endogenous porphyrin activation) are the same regardless of delivery method. What changes between a clinical laser and an at-home LED is power density and the ability to direct light into deep periodontal pockets. For the gumline and shallow-to-moderate pockets where LED light can reach, the mechanism operates identically.

Why Red and Blue Light Work Better Together for Periodontitis

Periodontitis is a three-sided problem: bacterial infection triggers inflammation, inflammation destroys tissue and bone, and the destroyed environment creates conditions where more bacteria thrive. Treating one side helps. Treating all three breaks the cycle.

Red light reduces the inflammation driving tissue and bone destruction, restores mitochondrial energy production in compromised periodontal cells, stimulates cellular repair, activates bone regeneration pathways, strengthens the gum's innate immune defense, and improves blood flow to compromised tissue. Blue light kills the bacteria that trigger the inflammation in the first place (using their own pigments, with no resistance risk) while also contributing to hard-tissue differentiation through the TRPV1 pathway and supporting wound healing through collagen deposition and cell migration. The mechanisms are independent: red light works through cytochrome c oxidase in human cells, blue light works through endogenous porphyrins in bacterial cells and through TRPV1 for tissue repair. A combined-wavelength approach addresses multiple drivers simultaneously.

For more on all the mechanisms through which red and blue light work in the mouth, see the CuraYou Oral Health blog.

Periodontitis and Systemic Health: Why This Matters Beyond the Mouth

One of the most significant developments in periodontal research over the past decade is the recognition that periodontitis is a systemic health condition, not just a dental one.

The 2023 EFP/WONCA consensus confirmed that periodontitis is independently associated with cardiovascular disease (increased risk of myocardial infarction and stroke), type 2 diabetes (bidirectional relationship), COPD, obstructive sleep apnea, and adverse COVID-19 outcomes. The report recommended that oral health professionals advise periodontitis patients that their cardiovascular risk is elevated and that medical practitioners include periodontal screening in the management of diabetic patients (Herrera et al., 2023).

A 2025 review in the Journal of Dental Research identified the mechanistic pathways: periodontitis drives metabolic dysfunction through systemic inflammation, insulin resistance, and oral dysbiosis that depletes nitrate-reducing bacteria and impairs nitric oxide pathways. Periodontal therapy was found to reduce HbA1c by approximately 0.43%, a metabolically meaningful reduction (Graves et al., 2025).

The relevance to light therapy is direct. The Gong 2025 meta-analysis demonstrated that adding PBM to periodontal treatment in diabetic patients improved not only periodontal outcomes (probing depth, clinical attachment level) but also systemic inflammation markers (hs-CRP, TNF-α) and fasting blood glucose. This is not separate research claiming light therapy helps diabetes. This is periodontal research showing that better periodontal treatment, enhanced by PBM, produces better systemic outcomes in patients whose periodontitis and diabetes reinforce each other.

Conclusion

Periodontitis destroys the structures that hold teeth in place (bone, ligament, attachment) and drives systemic inflammation linked to cardiovascular disease, diabetes, and respiratory disease. Red and blue light therapy addresses the disease from multiple directions through distinct, well-characterized biological mechanisms confirmed across dozens of independent peer-reviewed studies.

Red light increases cellular energy production, reduces the inflammatory cytokines that drive tissue and bone destruction, restores mitochondrial function in compromised periodontal cells, clears oxidative stress, activates molecular bone regeneration pathways (RUNX2, BMP-2, COL-1), stimulates periodontal ligament stem cell differentiation, strengthens the gum's innate immune defense, and improves blood flow to compromised tissue. Blue light kills the specific bacteria behind periodontitis using their own pigments (in the anaerobic conditions where they actually live) disrupts their replication, drives hard-tissue differentiation through the TRPV1 calcium channel pathway, supports wound healing, and works without chemicals, without resistance risk, and without harming healthy tissue.

The clinical evidence has matured substantially. Multiple meta-analyses pooling data from hundreds of patients across dozens of randomized controlled trials show statistically significant improvements in probing depth and clinical attachment level when PBM is added to standard periodontal care. In diabetic patients, those improvements extend to systemic inflammation and glycemic markers. The biology is strong. The clinical direction is consistent. The formal endorsement from dental authorities is pending, because the protocol standardization the field needs is still in progress.

For someone with periodontitis who wants to support the healing biology alongside professional care and consistent oral hygiene, red and blue light therapy offers a drug-free, non-invasive approach with a genuine and growing evidence base. The boundaries around what remains unproven are clearly marked above. With that information, the decision is yours.

For more research-backed articles on oral health and light therapy, visit the CuraYou Oral Health blog.